Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 1, 2008, Pages 53-61

  Wada, Yoshihiro ^a   Kikuchi, Ken ^a   Takahashi, Wataru ^a   Honda, Jiro ^a   Nakanishi, Juro ^a   Matsumoto, Koichiro ^b   Kuwahara, Tomohiro ^a   Kai, Nobuyuki ^a   Kikukawa, Hiroaki ^c   Ueda, Shoichi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

Author keywords

Docetaxel; Doxifluridine; Estramustine phosphate; Hormone refractory prostate cancer

Indexed keywords

ANDROGEN; DEXAMETHASONE; DOCETAXEL; DOXIFLURIDINE; ESTRAMUSTINE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DESQUAMATION; DIARRHEA; DRUG EFFICACY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HEADACHE; HORMONAL THERAPY; HUMAN; LOW DRUG DOSE; LUNG THROMBOSIS; MALE; NAIL DISEASE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SLEEP DISORDER; SMELLING DISORDER; STOMATITIS; SWEAT GLAND DISEASE; TASTE DISORDER; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; ESTRAMUSTINE; FLOXURIDINE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; JAPAN; MALE; MIDDLE AGED; NEUTROPENIA; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SURVIVAL RATE; TAXOIDS;

EID: 34848914531     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0445-4     Document Type: Article

References (40)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ (2004) American cancer society cancer statistics. CA Cancer J Clin 54:8-29
2. Cancer Statistics in Japan 2005 (2005), Electrical published. The Editorial Board of the Cancer Statistics in Japan. Foundation for Promotion of Cancer Research (FPCR), Tokyo, Japan
3. Vital Statistics of Japan, Statistics and Information Department. Minister's Secretariat, Ministry of Health, Labor and Welfare, Tokyo
4. Papatsoris AG, Papavassiliou AG (2001) Prostate cancer: horizons in the development of novel anti cancer strategies. Curr Med Chem Anticancer Agents 1:47-70
5. Petrylak D (2005) Therapeutic options in androgen-independent prostate cancer: building on docetaxel. BJU Int 2:41-46
6. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520
7. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512
8. Miyoshi Y, Uemura H, Nakamura M, Hasumi H, Sugiura S, Makiyama K, Nakaigawa N, Kishida T, Ogawa T, Yao M, Kubota Y (2005) Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients. Int J Clin Oncol 10:182-186
9. Li Y, Hussain M, Sarkar SH, Eliason J, Li R, Sarkar FH (2005) Gene expression profiling revealed novel mechanism of action of Taxotere and Furtulon in prostate cancer cells. BMC Cancer 18:5-7
10. Fischel JL, Ferrero JM, Formento P, Ciccolini J, Renee N, Formento JL, Milano G (2005) Taxotere-5′-deoxy-5-fluorouridine combination on hormone-refractory human prostate cancer cells. Anticancer Drugs 16:309-316
11. Kitamura T (2001) Necessity of re-evaluation of estramustine sodium (estramustine) as a treatment option for first-line monotherapy in advanced prostate cancer. Int J Urol 8:33-36
12. Bastida E, Escolar G, Almirall L, Ordinas A (1986) Platelet activation induced by a human neuroblastoma tumor cell line is reduced by prior administration of ticlopidine. Thromb Haemost 55:333-337
13. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G et al (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-specific antigen working group. J Clin Oncol 17:3461-3467
14. WHO criteria (1979) In: WHO handbook for reporting results of cancer treatment. World Health Organization, Geneva (Offset publication no. 48)
15. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11:570-579
16. Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ (1997) Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 50:920-928
17. Common toxicity criteria of the national cancer institute (version 2)
18. Sinibaldi VJ, Carducci MA, Cooper SM, Laufer M, Zahurak M, Eisenberger MA (2002) Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 94:1457-1465
19. Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, Hussain A, Small EJ, Vogelzang NJ (2001) Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 19:2509-2516
20. Pienta KJ (2001) Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol 28:3-7
21. Khan MA, Carducci MA, Partin AW (2003) The evolving role of docetaxel in the management of androgen independent prostate cancer. J Urol 170:1709-1716
22. Friedland D, Cohen J, Miller R Jr, Voloshin M, Gluckman R, Lembersky B, Zidar B, Keating M, Reilly N, Dimitt B (1999) A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 26:19-23
23. Berry W, Dakhil S, Gregurich MA, Asmar L (2001) Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 28:8-15
24. Beer TM, Pierce WC, Lowe BA, Henner WD (2001) Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 12:1273-1279
25. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oralfluoropyrimidine carbamate, capecitabine, which generates 5 fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274-1281
26. Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, Ishitsuka H (1998) Tumor selective delivery of 5 fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55:1091-1097
27. Niitani H, Kimura K, Saito T, Nakao I, Abe O, Urushizaki I, Ohta K, Yoshida Y, Kimura T, Kurihara M, Takeda C, Taguchi T, Terasawa T, Tominaga K, Furue H, Wakui A, Ogawa N (1985) Phase II study of 5′-deoxy 5-fluorouridine (5′-DFUR) on patients with malignant cancer. Multi-institutional cooperative study. Jpn J Cancer Chemother 12:2044-2051
28. Han JY, Lee DH, Kim HY, Hong EK, Yoon SM, Chun JH, Lee HG, Lee SY, Shin EH, Lee JS (2003) A phase II study of weekly docetaxel plus capecitabine for patients with advanced non-small cell lung carcinoma. Cancer 98:1918-1924
29. McDonald F, Miles D (2003) Xeloda and Taxotere: a review of the development of the combination for use in metastatic breast cancer. Int J Clin Pract 57:530-534
30. Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M, Roth B (1999) Vinblastine versus vinblastine plus oral estramustine for patients with hormone-refractory prostate cancer: a hoosier oncology group and fox chase network phase II trial. J Clin Oncol 17:3160-3166
31. Eisenberger MA (2002) Phase II evaluation of docetaxel plus one-day oral estramustine in the treatment of patients with androgen independent prostate carcinoma. Cancer 94:1457-1465
32. Petrylak DP, Macarthur R, O'Connor J, Shelton G, Weitzman A, Judge T, England-Owen C, Zuech N, Pfaff C, Newhouse J, Bagiella E, Hetjan D, Sawczuk I, Benson M, Olsson C (1999) Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. Semin Oncol 26:28-33
33. Kreis W, Budman DR, Fetten J, Gonzales AL, Barile B, Vinciguerra V (1999) Phase I trial of the combination of daily estramustine and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 10:33-38
34. Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, Small EJ, Cancer, Leukemia Group B 99813 (2003) A phase II study of estramustine, docetaxel, and carboplatin with granulocyte colony-stimulating factor support in patients with hormone-refractory prostate carcinoma. Cancer 98:2592-2598
35. Oh WK, Hagmann E, Manola J, George DJ, Gilligan TD, Jacobson JO, Smith MR, Kaufman DS, Kantoff PW (2005) A phase II study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Clin Cancer Res 11:284-289
36. Safarinejad MR (2005) Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer. Urol Oncol 23:93-101
37. Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Bessard ACH, Linassier C, Scotte F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM (2005) Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 23:3343-3351
38. Font A, Murias A, Arroyo FR, Martin C, Areal J, Sanchez JJ, Santiago JA, Constenla M, Saladie JM, Rosell R (2005) Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study. Ann Oncol 16:419-424
39. Efstathiou E, Bozas G, Kostakopoulos A, Kastritis E, Deliveliotis C, Antoniou N, Skarlos D, Papadimitriou C, Dimopoulos MA, Bamias A (2005) Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment. Urology 65:126-130
40. Wilding G, Soulie P, Trump D, Das-Gupta A, Small E (2006) Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer. Cancer 106:1917-1924